TherapeuticsMD | TXMD - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Novo Nordisk DKK 90.92B 468.3B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
TherapeuticsMD USD 40.13M 1.96M 2024-06